Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2006-04-28 | Dr. Chaplin has served as our Chief Scientific Officer and Head of Research and Development since July 2000. From 1999 to 2000, Dr. Chaplin served as Vice President of Oncology at Aventis Pharma in Paris. Prior to the merger of Rhone Poulenc Rorer ("RPR") with Hoechst Marion Roussell, Dr. Chaplin was Senior Director of Oncology at RPR from 1998 to 1999. From 1992 to 1998, Dr. Chaplin headed up the Cancer Research Campaign's ("CRC") Tumor Microcirculation Group, based at the Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, London. |
| 2007-04-27 | Dr. Chaplin has served as Chief Scientific Officer and Head of Research and Development with experience in oncology and cancer research, but no software-related skills are mentioned. |
| 2008-04-28 | Dr. Chaplin has served as our Chief Scientific Officer and Head of Research and Development since July 2000. His experience is in oncology and cancer research. |
| 2013-06-13 | Dr. Chaplin has a B.Sc. in chemistry from the University of Essex, a M.Sc. in pharmacology from the University of Southampton, and completed his Ph.D. in tumor biology at the University of London. |
| 2014-04-30 | Dr. Chaplin has a B.Sc. in chemistry from the University of Essex, a M.Sc. in pharmacology from the University of Southampton, and completed his Ph.D. in tumor biology at the University of London. |
Data sourced from SEC filings. Last updated: 2025-10-12